erythromycin 2'-acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

erythromycin 2'-acetate: prodrug of erythromycin; 2'-acetyl ester & stearate salt of erythromycin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	114919
CHEMBL ID	2110577
CHEBI ID	135882
MeSH ID	M0158790

Synonyms (14)

Synonym
2'-acetylerythromycin
CHEBI:135882
992-69-8
s3q5941gcw ,
2'-acetylerythromycin a
erythromycin 2'-acetate
2'-o-acetylerythromycin a
unii-s3q5941gcw
erythromycin, 2'-acetate
CHEMBL2110577
C21595
CVBHEIRZLPKMSH-SNWVVRALSA-N
2'-o-acetyl-erythromycin a
Q27893913

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
" It is concluded, that food does not affect the mean bioavailability of erythromycin acistrate neither the mean rate of absorption but in some subjects the absorption from enteric coated tablets might be significantly delayed."	( Effect of food on absorption and hydrolysis of erythromycin acistrate. Haataja, H; Järvinen, A; Mattila, J; Nykänen, S, 1992)	0.28
" Its bioavailability from hard gelatin capsules containing the drug with or without sodium bicarbonate was studied in healthy volunteers."	( Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate. Marvola, M; Nokelainen, M; Nykänen, S, 1991)	0.28
" Hence EA has a good bioavailability essential for treatment and prophylaxis of bacterial infections in dentistry."	( Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study. Gordin, A; Kokkonen, P; Lehtinen, R; Peltola, J; Pohto, P; Tuominen, RK; Wikberg, R, 1991)	0.28
" The bioavailability of EA was slightly inferior to that of ES."	( Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice. Hanhijärvi, H; Havas, A; Komulainen, H; Männistö, PT; Rauramaa, V; Vuorela, A, 1989)	0.28
" In Study II, the effect of food on the bioavailability of the two EB preparations was studied after a single dose of 500 mg (2 x 250 mg enterocoated tablets) and after multiple dosing (2 x 250 mg tid)."	( Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state. Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A, 1988)	0.27

Dosage Studied

Excerpt	Relevance	Reference
" The dosage of EA was 400 mg tid and that of ES 500 mg tid."	( Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema. Antikainen, R; Brandt, H; Gordin, A; Salo, OP, 1988)	0.27
" The dosage of EA was 400 mg tid and that of the two erythromycin base preparations 500 mg tid."	( Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base. Flygare, U; Hildén, M; Hurme, J; Järvinen, H; Leskinen, J; Pynnönen, S; Riikonen, A; Salomaa, V; Seuri, M; Wuolijoki, E, 1988)	0.27
" The dosage of EA was 400 mg tid and that of ES 500 mg tid."	( Erythromycin acistrate and erythromycin stearate in the treatment of non-gonococcal urethritis. Antikainen, R; Gordin, A; Rostila, T; Visa, K, 1988)	0.27
" In Study II, the effect of food on the bioavailability of the two EB preparations was studied after a single dose of 500 mg (2 x 250 mg enterocoated tablets) and after multiple dosing (2 x 250 mg tid)."	( Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state. Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A, 1988)	0.27
"The drug concentration in plasma, suction skin blister fluid (SBF), urine and saliva after repeated dosage of either erythromycin acistrate (EA) or enterocoated pellets of erythromycin base (EB) was studied in young healthy volunteers with a cross-over design in two separate studies."	( Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base. Haataja, H; Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A, 1988)	0.27
"Concentrations of erythromycin and 2'-acetyl erythromycin were analysed in serum or plasma and tonsil tissue after repeated dosage of erythromycin acistrate (EA), a new erythromycin prodrug, in two separate studies in 61 young patients."	( Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis. Antikainen, R; Gordin, A; Haataja, H; Männistö, PT; Savolainen, S; Tuominen, RK; Ylikoski, J, 1988)	0.27
" The dosage of EA was 400 mg tid and that of EB 500 mg tid, and the treatment period ranged from seven to 14 days."	( Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections. Antikainen, R; Gordin, A; Hulmi, S; Kalima, S; Mäkelä, P, 1988)	0.27
" The dosage of EA was 400 mg tid and that of EB 500 mg tid."	( Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts. Antikainen, R; Gordin, A; Salmi, HA, 1988)	0.27
" Due to prolonged half-life it is more suitable for twice daily dosing than the conventional erythromycin preparations."	( Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Lehtonen, L; Wiesner, B; Wilen-Rosenqvist, G, 1993)	0.29
" endometrium, myometrium, ovary and Fallopian tube, as well as in plasma, were determined after oral dosing of erythromycin acistrate (EA, CAS 96128-89-1), a erythromycin prodrug."	( Erythromycin and 2'-acetyl erythromycin concentrations in plasma and pelvic tissues after repeated doses of erythromycin acistrate. Karhunen, M; Kokkonen, P; Lehtonen, L; Tuominen, R; Wikberg, R, 1993)	0.29

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
aminoglycoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (57.69)	18.7374
1990's	10 (38.46)	18.2507
2000's	1 (3.85)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.66 (24.57)
Research Supply Index	3.74 (2.92)
Research Growth Index	4.40 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.66)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	14 (51.85%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (48.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	1.97	1	0	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	3.35	1	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
dipivefrin dipivefrin: used in treatment of both primary & open angle glaucoma; RN given refers to (+-)-isomer. dipivefrin : The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.	1.99	1	0	ethanolamines; pivalate ester	adrenergic agonist; antiglaucoma drug; ophthalmology drug; prodrug; sympathomimetic agent
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	1.99	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
erythromycin stearate [no description available]	6.04	8	4	aminoglycoside
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	8.27	26	13	cyclic ketone; erythromycin
erythromycin ethylsuccinate Erythromycin Ethylsuccinate: A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin ethylsuccinate : A erythromycin derivative that is erythromycin A in which the hydroxy group at position 3R is substituted by a (4-ethoxy-4-oxobutanoyl)oxy group. It is used for the treatment of a wide variety of bacterial infections.	3.36	1	1	cyclic ketone; erythromycin derivative; ethyl ester; succinate ester
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	1.97	1	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	3.35	1	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	1.99	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	1.99	1	0	L-valyl ester	antiviral drug

Condition	Relationship Strength	Studies	Trials
Infections, Respiratory [description not available]	6.17	6	6
Acute Disease Disease having a short and relatively severe course.	4.97	3	3
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	3.37	1	1
Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.	3.37	1	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	6.17	6	6
Infectious Skin Diseases [description not available]	4.32	2	2
Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses.	4.32	2	2
Blood Poisoning [description not available]	1.97	1	0
Periapical Cyst [description not available]	1.97	1	0
Dental Granuloma [description not available]	1.97	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	1.97	1	0
Primary Peritonitis [description not available]	1.97	1	0
Infections, Staphylococcal [description not available]	1.97	1	0
Group A Strep Infection [description not available]	3.76	2	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	1.97	1	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	1.97	1	0
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	3.76	2	1
Cholera Infantum [description not available]	3.36	1	1
Eczema, Atopic [description not available]	3.35	1	1
Infections, Staphylococcal Skin [description not available]	3.35	1	1
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	3.35	1	1
Staphylococcal Skin Infections Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.	3.35	1	1
Infections, Chlamydia [description not available]	3.35	1	1
Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA.	3.35	1	1
Urethritis Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both.	3.35	1	1
Bleb [description not available]	3.35	1	1
Chronic Illness [description not available]	3.35	1	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.35	1	1
Tonsillitis Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.	3.35	1	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.97	1	0
Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.	1.97	1	0
Viral Diseases [description not available]	3.35	1	1
Virus Diseases A general term for diseases caused by viruses.	3.35	1	1

chemdatabank.com